The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Genetic risk assessment for hereditary RCC: Report from the consensus panel meeting.
 
Michael Daneshvar
No Relationships to Disclose
 
Neil Mendhiratta
No Relationships to Disclose
 
Ramaprasad Srinivasan
Research Funding - AstraZeneca (Inst); Calithera Biosciences (Inst); Peloton Therapeutics (Inst); Sanofi (Inst)
 
Eric Jonasch
Consulting or Advisory Role - Eisai; Exelixis; Genentech/Roche; Ipsen; Novartis; Peloton Therapeutics; Pfizer
Research Funding - Exelixis; Novartis; Peloton Therapeutics; Pfizer
Travel, Accommodations, Expenses - Pfizer
 
Mark Wayne Ball
No Relationships to Disclose
 
Adam R Metwali
No Relationships to Disclose
 
James Brugarolas
Consulting or Advisory Role - Arrowhead Pharmaceuticals; Exelixis
Research Funding - Arrowhead Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Patent of HIF-2 biomarker (Inst); Patent pertaining HIF2a resistance mutations (Inst)
Travel, Accommodations, Expenses - Exelixis
 
Eric A. Singer
Research Funding - Astellas Medivation
 
Katherine Nathanson
No Relationships to Disclose
 
Phillip M. Pierorazio
No Relationships to Disclose
 
Ronald S Boris
No Relationships to Disclose
 
Antonio Finelli
Stock and Other Ownership Interests - Abbvie; Bristol-Myers Squibb
Honoraria - Abbvie; Amgen; Astellas Pharma; Bayer; Ipsen; Janssen Oncology; Roche Canada; Tersera
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; Bayer; Janssen Oncology; Tersera
Travel, Accommodations, Expenses - TerSera
 
Sumanta K. Pal
Honoraria - Astellas Pharma; Medivation; Novartis
Consulting or Advisory Role - Astellas Pharma; Aveo; Bristol-Myers Squibb; Eisai; Exelixis; Genentech; Ipsen; Myriad Pharmaceuticals; Novartis; Pfizer
Research Funding - Medivation
 
A. Ari Hakimi
No Relationships to Disclose
 
Alexander Kutikov
Leadership - Visible Health
Stock and Other Ownership Interests - Visible Health
Consulting or Advisory Role - Pfizer; UroToday
Travel, Accommodations, Expenses - Pfizer
 
Othon Iliopoulos
Consulting or Advisory Role - FKS
Patents, Royalties, Other Intellectual Property - MGH 02363—Small molecule inhibitors of hypoxia inducible-factor as anti-angiogenic compounds Issued patents: 8,691,866 and 9,604,958 Pending US patent applications: 15/431,967 (PCT application number: PCT/US09/067555); MGH 21488—Metabolic gene, enzyme, and flux targets for cancer therapy Issued patent: 10,064,885
 
W. Marston Linehan
No Relationships to Disclose
 
Brian M. Shuch
Honoraria - Bristol-Myers Squibb; peloton therapeutics
Consulting or Advisory Role - Bristol-Myers Squibb; Peleton; Pfizer
 
Gennady Bratslavsky
No Relationships to Disclose